HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QHC For Vitamin D, Omega-3 Helping Prevent Autoimmune Conditions Has VITAL Data Support

Executive Summary

Trial for 5.3 years with more than 25,000 consumers 50 and older pointing to a link between vitamin D and imegta-3s and reducing autoimmune disease isn’t the first with results from VITAL. “It's a big one that we've been watching for a number of years. And it's exciting, some exciting outcomes,” says CRN scientific and regulatory affairs exec Andrea Wong.

You may also be interested in...

Vitamin D RDA Changes Needed Because D3 Has More Nutrient Impact Than D2, UK Study Suggests

Vitamin D3 stimulates immune system and raises nutrient's level in body more than vitamin D2, study finds. Study also recommend further research to investigate different physiological roles for D2 and D3.

Magnesium Qualified Health Claims For Reducing Risk Of Hypertension Authorized In US

CFSAN decides on Center for Magnesium Education and Research LLC's 2016 petition requesting FDA authorize a qualified health claim about relationship between magnesium and reduced risk of high blood pressure, or hypertension.

Vitamin D, Omega-3 No Help For Diabetics Against CKD, VITAL Data Show

In latest study casting doubt on the nutrients' effect on chronic illness, researchers find vitamin D and fish oil ineffective in staving off type 2 diabetics' kidney failure. Editorial also published in JAMA says further research is needed to analyze the nutrients’ possible benefits to diabetics with chronic kidney disease.

Related Content


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts